Fundamental Analysis of ITERUM THERAPEUTICS PLC(NASDAQ:ITRM) stock

Fundamental Rating

Overall ITRM gets a fundamental rating of 1 out of 10. We evaluated ITRM against 198 industry peers in the Pharmaceuticals industry. ITRM has a bad profitability rating. Also its financial health evaluation is rather negative. ITRM is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

ITRM had negative earnings in the past year.

ITRM had a negative operating cash flow in the past year.

In the past 5 years ITRM always reported negative net income.

ITRM had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

ITRM's Return On Assets of -146.13% is on the low side compared to the rest of the industry. ITRM is outperformed by 87.69% of its industry peers.

		Industry Rank	Sector Rank
ROA	-146.13%
ROE	N/A
ROIC	N/A

ROA(3y)-104.22%

ROA(5y)-174.36%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ITRM so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ITRM has more shares outstanding than it did 1 year ago.

The number of shares outstanding for ITRM has been increased compared to 5 years ago.

Compared to 1 year ago, ITRM has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -29.55, we must say that ITRM is in the distress zone and has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -29.55, ITRM is doing worse than 90.77% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-29.55

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 1.89 indicates that ITRM should not have too much problems paying its short term obligations.

ITRM has a Current ratio of 1.89. This is in the lower half of the industry: ITRM underperforms 66.67% of its industry peers.

ITRM has a Quick Ratio of 1.89. This is a normal value and indicates that ITRM is financially healthy and should not expect problems in meeting its short term obligations.

ITRM's Quick ratio of 1.89 is on the low side compared to the rest of the industry. ITRM is outperformed by 62.05% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.89
Quick Ratio	1.89

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ITRM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.24%, which is quite good.

EPS 1Y (TTM)18.24%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-129.27%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 20.60% on average over the next years. This is a very strong growth

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y20.47%

EPS Next 2Y28.51%

EPS Next 3Y21.58%

EPS Next 5Y20.6%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ITRM. In the last year negative earnings were reported.

Also next year ITRM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ITRM's earnings are expected to grow with 21.58% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y28.51%

EPS Next 3Y21.58%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ITRM!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ITERUM THERAPEUTICS PLC

NASDAQ:ITRM (5/1/2024, 6:26:57 PM)

After market: 1.6 +0.01 (+0.63%)

1.59

+0.06 (+3.92%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap26.12M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-146.13%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	1.89
Quick Ratio	1.89
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)18.24%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y20.47%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

ITERUM THERAPEUTICS PLC (ITRM)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens